CABA
Cabaletta Bio, Inc.
Set alert
- YTD
- -31.05%
- 1 year
- -38.87%
- Open
- 1.54
- Prev close
- 1.59
- Mkt cap
- 256.01M
- Vol
- 3.76M
- Avg vol
- 5.20M
- EPS
- -1.51
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.43
- High
- 1.59
- Forward P/E
- -0.98
- Beta
- 2.42
- Short ratio
- 4.26
- Inst. own
- 100.47%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 3.53
- 200-d avg
- 8.16
- 1y target
- 22.22
Key statistics
- Market cap
- 115.35M
- Enterprise value
- -11.18M
- Trailing P/E
- 0.00
- Forward P/E
- -0.98
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.48
- EPS (TTM)
- -2.16
- Beta
- 2.42
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -45.62M
- Total cash
- 203.22M
- Total debt
- 7.40M
- Return on equity
- -48.16%
- Shares outstanding
- 48.88M
- Short % of float
- 7.84%
- 50-day average
- 3.53
- 200-day average
- 8.16
Analyst view
Consensus: strong buy
- Target (low)
- 6.00
- Target (mean)
- 22.22
- Target (high)
- 35.00
- Strong buy2
- Buy8
- Hold2
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.64072.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.59 | -0.62 | -0.03 | -5.08% |
| Aug 8, 2024 | Jun 1, 2024 | -0.55 | -0.56 | -0.01 | -1.82% |
| Aug 8, 2024 | Jun 1, 2024 | -0.55 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | -0.48 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | -0.48 | -0.51 | -0.03 | -6.25% |
| Mar 21, 2024 | Dec 1, 2023 | -0.39 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 20, 2024 | Evercore ISI Group | down | Outperform | In-Line |
| Dec 19, 2024 | Wells Fargo | down | Overweight | Equal-Weight |
| Nov 18, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 15, 2024 | Wells Fargo | main | Overweight | Overweight |
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 10, 2024 | UBS | init | — | Buy |
About Cabaletta Bio, Inc.
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cabalettabio.com
News
- Cabaletta Bio: 40% Sell-Off Creates An Opportunity Despite Cash Concerns
- Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Cabaletta Bio, Inc. (CABA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $16 Price Target
- Cango, Nio And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
- Cabaletta Bio to Participate in Upcoming Investor Conferences
- Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Lowers Price Target to $3
- Cabaletta Bio Q2 EPS $(0.34) Beats $(0.39) Estimate
- Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
- Cabaletta Bio: The Market Sold The EULAR News, I'm Buying
Your note
Sign in to keep a note on CABA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BINDER GWENDOLYN | Officer | Conversion of Exercise of derivative security | Jan 18, 2024 | 20,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Jennison Associates LLC | 11.52% | 5,632,681 | 13.29M | Sep 29, 2024 |
| Blackrock Inc. | 9.81% | 4,793,484 | 11.31M | Sep 29, 2024 |
| Fred Alger Management, LLC | 8.43% | 4,119,394 | 9.72M | Sep 29, 2024 |
| T. Rowe Price Investment Management, Inc. | 7.52% | 3,673,724 | 8.67M | Sep 29, 2024 |
| Adage Capital Partners GP L.L.C. | 6.21% | 3,036,645 | 7.17M | Sep 29, 2024 |
| Bain Capital Life Sciences Investors, LLC | 5.65% | 2,760,888 | 6.52M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) Small-Cap Value Fund | 4.18% | 2,041,663 | 4.82M | Sep 29, 2024 |
| Alger Small Cap Focus Fund | 3.11% | 1,519,064 | 3.58M | Jul 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.87% | 1,401,191 | 3.31M | Sep 29, 2024 |
| PGIM Jennison Health Sciences Fd | 2.82% | 1,378,804 | 3.25M | Oct 30, 2024 |
| PGIM Jennison Small Company Fd | 2.63% | 1,286,536 | 3.04M | Oct 30, 2024 |
| iShares Russell 2000 ETF | 2.29% | 1,116,866 | 2.64M | Oct 30, 2024 |